Novo Nordisk maintains a Buy rating driven by strong uptake of its oral obesity drug Wegovy, which has captured 90% of the US oral obesity market with over 5 million prescriptions since launch. The company’s robust GLP-1 franchise and upcoming drug approvals, like CagriSema, position it well against competitors such as Eli Lilly. Despite competitive and pricing challenges, Novo Nordisk’s valuation remains attractive with a 2028 price-to-earnings ratio of 12.4 and low net debt, suggesting the market may be underestimating its growth potential and execution capabilities.
Novo Nordisk remains a strong buy as it trades at a low 12.5x P/E ratio despite robust growth and expanding international operations, which now account for 65% of group growth. The company’s EUCAN obesity care segment grew 52% at constant exchange ra...
Eli Lilly shows strong performance with 48% revenue growth driven by GLP-1 drugs Mounjaro and Zepbound, raising 2026 guidance significantly. Novo Nordisk struggles with pricing cuts and pipeline setbacks, keeping its stock range-bound despite solid s...
